These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39020518)

  • 1. Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study).
    Zhang W; Tang Y; Wei L; Liu S; Wang W; Chi Y; Wang Y; Kang W; Huang W; Deng F; Li H; Ma H; Jiang L; Ding Z; Feng L; Li Y; Chen Y; Zhou H; Hu C; Jin J
    Colorectal Dis; 2024 Sep; 26(9):1732-1740. PubMed ID: 39020518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH).
    Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
    BMC Cancer; 2022 Mar; 22(1):274. PubMed ID: 35291966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.
    Alvarez JA; Shi Q; Dasari A; Garcia-Aguilar J; Sanoff H; George TJ; Hong T; Yothers G; Philip P; Nelson G; Al Baghdadi T; Alese OB; Zambare W; Omer D; Verheij FS; Bercz A; Kim MJ; Buckley J; Williams H; George M; Garcia R; Gallagher P; O'Reilly EM; Meyerhardt JA; Crawley J; Shergill A; Horvat N; Romesser PB; Hall W; Smith JJ
    BMC Cancer; 2024 Jul; 24(1):901. PubMed ID: 39060961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
    Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353
    [No Abstract]   [Full Text] [Related]  

  • 5. The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and Cadonilimab for locally advanced rectal cancer: a protocol of a phase II study.
    Xu T; Feng L; Zhang W; Li H; Ma H; Abulimiti M; Tan Y; Deng F; Huang W; Zou S; Kang W; Jiang L; Wang Y; Hu C; Chen Y; Zhou H; Tang Y; Jin J
    BMC Cancer; 2024 Apr; 24(1):501. PubMed ID: 38641773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
    Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F
    BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial.
    Kim MJ; Lee DW; Kang HC; Park JW; Ryoo SB; Han SW; Kim KS; Chie EK; Oh JH; Jeong WK; Kim BH; Nam EM; Jeong SY
    BMC Cancer; 2023 Aug; 23(1):734. PubMed ID: 37553666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Node-sparing modified short-course Radiotherapy Combined with CAPOX and Tislelizumab for locally Advanced MSS of Middle and low rectal Cancer (mRCAT): an open-label, single-arm, prospective, multicentre clinical trial.
    Cai C; Zhang X; Sun X; Wang H; Chen E; Chen L; Gu B; Wang J; Huang X; Lao W; Wang X; Chen M; Ding S; Du J; Song Z
    BMC Cancer; 2024 Oct; 24(1):1247. PubMed ID: 39385104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
    Hanna CR; O'Cathail SM; Graham JS; Saunders M; Samuel L; Harrison M; Devlin L; Edwards J; Gaya DR; Kelly CA; Lewsley LA; Maka N; Morrison P; Dinnett L; Dillon S; Gourlay J; Platt JJ; Thomson F; Adams RA; Roxburgh CSD
    Radiat Oncol; 2021 Aug; 16(1):163. PubMed ID: 34446053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
    Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
    BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
    BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
    Huang CY; Bai MH; Shen JW; Sun QQ; Feng YR; Chen QP; Mao W; Ju HX; Zhu J
    BMC Cancer; 2024 Jan; 24(1):57. PubMed ID: 38200410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study protocol of short-course radiotherapy combined with CAPOX and PD-1 inhibitor for locally advanced colon cancer: a randomised, prospective, multicentre, phase II trial (TORCH-C).
    Zhang H; Li Y; Xia F; Sun Y; Shen L; Wan J; Chen Y; Wang Y; Zhou M; Wu R; Zhou S; Wang Y; Liu F; Cai S; Zhang Z
    BMJ Open; 2024 Feb; 14(2):e079442. PubMed ID: 38309748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 20. Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial).
    Kang MK; Park SY; Park JS; Kim HJ; Kim JG; Kang BW; Baek JH; Cho SH; Seo AN; Kim DW; Kim J; Baek SJ; Kim JH; Kim JY; Ha GW; Park EJ; Park IJ; Kim CH; Kang H; Choi GS
    BMC Cancer; 2023 Nov; 23(1):1059. PubMed ID: 37923987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.